Last Updated : September 18, 2017
Details
FilesGeneric Name:
Rituximab
Project Status:
Complete
Therapeutic Area:
Acute Lymphoblastic Leukemia
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Rituxan
Project Line:
Reimbursement Review
Project Number:
PC0102-000
NOC Status at Filing:
Pre NOC
Strength:
200mg and 500mg vials
Tumour Type:
Leukemia
Indications:
Acute Lymphoblastic Leukemia
Funding Request:
In combination with standard of care chemotherapy for Philadelphia chromosome negative, CD20 antigen positive, B-cell precursor acute lymphoblastic leukemia in adults
Pre Noc Submission:
Yes
Sponsor:
Cancer Care Manitoba
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : September 18, 2017